Allos Therapeutics Announces Presentation of Updated Results From Phase 1/2 Trial of PDX in Patients With Aggressive Lymphomas a
10 November 2006 - 5:56AM
PR Newswire (US)
WESTMINSTER, Colo., Nov. 9 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that updated
results from a Phase 1/2 study evaluating the Company's novel
antifolate PDX (pralatrexate) in patients with relapsed or
refractory non-Hodgkin's lymphoma and Hodgkin's disease have been
accepted for presentation at the American Society of Hematology's
48th Annual Meeting, to be held December 9 - 12 in Orlando. Owen
O'Connor, M.D., Ph.D., Head of the Laboratory of Experimental
Therapeutics for Lymphoproliferative Malignancies, Lymphoma and
Development Chemotherapy Services, Memorial Sloan-Kettering Cancer
Center (MSKCC), is scheduled to report updated results from the
on-going study in an oral presentation titled "Pralatrexate (PDX)
Produces Durable Complete Remissions in Patients with Chemotherapy
Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the
MSKCC Phase I/II Experience" on Monday, December 11 at 11:45 AM ET.
A copy of the abstract (#556063) is currently available on the
American Society of Hematology's web site,
http://www.hematology.org/. About Allos Therapeutics, Inc. Allos
Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused on
the development and commercialization of small molecule
therapeutics for the treatment of cancer. The Company has two
product candidates in late-stage clinical development: EFAPROXYN
(efaproxiral), a radiation sensitizer currently under evaluation in
a pivotal Phase 3 trial in women with brain metastases originating
from breast cancer, and PDX (pralatrexate), a novel, next
generation antifolate currently under evaluation in a pivotal Phase
2 trial in patients with relapsed or refractory peripheral T-cell
lymphoma. The Company is also evaluating RH1, a targeted
chemotherapeutic agent, in a Phase 1 trial in patients with
advanced solid tumors. For additional information, please visit the
Company's website at http://www.allos.com/. Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties,
including those to be discussed in the presentation and others that
can be found in the "Risk Factors" section of the Company's Form
10-K for the year ended December 31, 2005 and in the Company's
periodic reports on Form 10-Q and Form 8-K. The Company does not
undertake any obligation to update any forward-looking statements
contained in the anticipated presentation as a result of new
information, future events or otherwise. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in the presentation. No forward-looking
statement can be guaranteed and actual events and results may
differ materially from those projected. DATASOURCE: Allos
Therapeutics, Inc. CONTACT: Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, Inc., +1-720-540-5227, Web
site: http://www.allos.com/ http://www.hematology.org/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More Allos Therapeutics (MM) News Articles